Suraksha Diagnostic Limited (SURAKSHA) fundamentals
Suraksha Diagnostic Limited is a listed company in Healthcare Services, part of the Healthcare sector, listed on the NSE as SURAKSHA (ISIN INE877V01027). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Suraksha Diagnostic Limited does
Suraksha Diagnostic Limited is an India-based company. The Company is primarily engaged in the business of running diagnostic centers for carrying out various pathological and radiological services. The Company offers integrated solutions for pathology and radiology testing, and medical consultation services to its customers through its operational network. Its services include Imaging, Neurology, Cardiology, Gastroenterology, and Pathology. Its Imaging services include X-Ray, DEXA scan, USG scan, CT scan and others. Its Neurology services include EEG, EMG, NCV. Its Cardiology services include Echocardiogram Test, Stress Test / Treadmill Test, Holter Monitoring, Color Doppler, Peripheral Doppler, and others. Its Pathology services include Microbiology, Cytogenetic, Serology, Molecular Biology, Histopathology, Cytopathology, Haematology, and others. Its Gastroenterology services include Upper GI Endoscopy, Sigmoidoscopy, Colonoscopy, Proctoscopy, Proctosigmoidoscopy, and others.
Valuation and market data
| Last close | ₹326.20 |
|---|---|
| Market capitalisation | ₹1,693 crore |
| Enterprise value | ₹1,770 crore |
| P/E (TTM) | 0.00 |
| Price to book | 8.05 |
| Price to sales (TTM) | 5.15 |
| Book value per share | ₹40.51 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Healthcare Services |
| Listed since | Fri Dec 06 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹305 crore | ₹47 crore | ₹34 crore | 0.00 |
| Mar 2025 | ₹253 crore | ₹44 crore | ₹33 crore | 6.42 |
| Mar 2024 | ₹222 crore | ₹33 crore | ₹24 crore | 4.57 |
| Mar 2023 | ₹194 crore | ₹8 crore | ₹7 crore | 1.35 |
| Mar 2022 | ₹226 crore | ₹33 crore | ₹24 crore | 344.22 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 49.1% |
|---|---|
| Foreign institutions (FII) | 13.5% |
| Mutual funds | 20.1% |
| Other domestic institutions | 3.2% |
| Retail and others | 14.2% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.